Fast Company

recognizes Celmatix

Named one of the world’s 50

most innovative companies

Read why

Introducing Fertilome

The world’s first

comprehensive genetic screen

for reproductive health

Offer Fertilome at your clinic

The future of

fertility is proactive

Learn about our vision

Celmatix is a next-generation women’s health company transforming the way women and their physicians leverage genomics and data to make more informed, proactive reproductive health decisions.

Our vision

Celmatix is committed to empowering women with genomic insights about their fertility and reproductive health.
00:00:00/00:00:00

Our products

Celmatix is dedicated to advancing women’s health by leveraging all available innovations in technology with data and genomics. Our research-based products help clinics optimize patient outcomes and improve the patient experience.

Fertilome

Fertilome is the world’s first comprehensive genetic screen that reveals what a woman's DNA says about her reproductive health and fertility potential. This next generation sequencing panel reveals factors significantly associated with the most common reproductive conditions in women.

Learn more

Polaris

Polaris is a real-time predictive analytics platform that helps fertility clinics streamline the onboarding experience, create tailored patient treatment plans and counsel patients through key inflection points.

Learn more

Data-driven discovery

By applying big data methods to proprietary clinical and genetic datasets, Celmatix has developed an unprecedented understanding of human reproductive function. These discoveries are driving a revolution in proactive fertility management.

We have built the world’s largest clinical dataset on fertility treatment outcomes.

We have identified over 5,200 unique regions of the human genome that impact a person’s fertility potential.

We founded the Personalized Reproductive Medicine (PReM) Initiative, a groundbreaking research alliance of leading academic institutions and fertility treatment centers across the United States, to investigate what an individual’s genetics and other metrics say about his or her overall fertility. The PReM Initiative's goal is to revolutionize how infertility is diagnosed, treated, and eventually, prevented.

23andMe

23andMe and Celmatix have embarked on an ambitious research collaboration to improve infertility outcomes.